Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances

NEPTUNE Clinical Guidance

Häftad, Engelska, 2022

1 059 kr

Beställningsvara. Skickas inom 7-10 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

There are global concerns about the proliferation and misuse of club drugs and novel psychoactive substances, yet we know little about their harms and research on clinical management and treatment remains limited. This book fills the knowledge gap by providing a detailed overview of the research evidence available to date. The book provides a framework that allows readers to understand this large number of new drugs, using classifications based on primary psychoactive effect. Within this framework, the book provides detailed reviews of the more commonly used drugs. Each chapter explores pharmacology, patterns and mode of use, acute and chronic harms, and clinical interventions supported by research evidence. An invaluable resource for clinical staff, this book will support clinicians working in the emergency department, substance misuse and addiction services, mental health services, primary care, sexual health services and more. It will also be of interest to academics and those developing drug policy.

Produktinformation

Utgivningsdatum2022-10-13
Mått187 x 245 x 18 mm
Vikt680 g
FormatHäftad
SpråkEngelska
Antal sidor348
FörlagCambridge University Press
ISBN9781009182133

Tillhör följande kategorier

Psykisk hälsovård inom Medicin

Dima Abdulrahim is Programme Manager and Principal Researcher for the NEPTUNE Project and Quality Lead of the Addictions Department of Central and North West London NHS Foundation Trust. She has been working in the drug treatment field for over thirty years. She is a previous Council member of the Advisory Council on the Misuse of Drugs. She co-authored Club Drugs and Novel Psychoactive Substances: The Clinician's Handbook (Cambridge University Press, 2020) with Owen Bowden-Jones and sits on the Editorial Board of Drugs, Habits and Social Policy (formerly Drugs and Alcohol Today). Owen Bowden-Jones is a Consultant in Addiction Psychiatry and an Honorary Professor at University College London, UK. In 2010 he founded the Club Drug Clinic, London, an innovative service offering treatment for club drugs and novel psychoactive substances. He is Chair of the Advisory Council on the Misuse of Drugs and national clinical adviser at the Office for Health Improvement. He is also a trustee of the Society for the Study of Addiction and a board member at the International Society for the Study of Emerging Drugs. His research interests include emerging drug harms, particularly in young people.

1. An Introduction to Club Drugs and Novel psychoactive substances; 2. Psychosocial interventions for club drugs and novel psychoactive substances; 3. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) Drug group: depressants; 4. New Benzodiazepine (BZD) NPS; 5. Synthetic Opioids NPS (fentanyl and non-fentanyl NPS); 6. Ketamine and other NPS with dissociative effects; 7. Nitrous oxide (N2O); 8. Stimulant Club Drugs and novel psychoactive substances; 9. 'Ecstasy'- MDMA, 3,4-methylenedioxymethamphetamine), MDMA analogues and drugs with similar effects; 10 . Methamphetamine; 11. Synthetic cathinones; 12. Hallucinogenic drugs; 13. Synthetic cannabinoid receptor agonists (SCRA).

'This book is a welcome addition to the previous 2015 NEPTUNE guidance. It provides a unique learning experience on what all clinicians should know about the misuse of club drugs and novel psychoactive substances. Capturing the latest trends of a dynamic drug market, the authors pulled together the best available evidence on a variety of substances to support the improvement of clinical practice. Whether you consult chapters of special interest or read the entire book, you can be assured that you will have been exposed to the most comprehensive work available on the clinical management of the harms of novel psychoactive substances. Highly recommended.' Ornella Corazza, Ph.D., Professor of Addiction Science, University of Hertfordshire, UK, and President of the International Society for the Study of Emerging Drugs